Does the media prefer ALLO or ACOG?

In the previous week, Alpha Cognition had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.19 beat Alpha Cognition's score of 0.85 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACOG or CADL?

In the previous week, Alpha Cognition had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.03 beat Alpha Cognition's score of 0.85 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CRMD or ACOG?

CorMedix has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 2.08 $163.05M $2.13 3.88 Alpha Cognition $10.22M 17.15 -$20.67M -$1.35 N/A

Does the media prefer CRMD or ACOG?

In the previous week, Alpha Cognition had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Alpha Cognition and 2 mentions for CorMedix. CorMedix's average media sentiment score of 0.86 beat Alpha Cognition's score of 0.85 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACOG or FDMT?

In the previous week, Alpha Cognition had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 6 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Alpha Cognition's score of 0.85 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DRUG or ACOG?

In the previous week, Alpha Cognition had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Alpha Cognition and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.03 beat Alpha Cognition's score of 0.85 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alpha Cognition (ACOG) Competitors

$8.05 -0.33 (-3.94%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$7.92 -0.13 (-1.66%)

As of 07/14/2026 06:36 PM Eastern

Compare

ACOG vs. ALLO, CADL, CRMD, FDMT, and DRUG

Should you buy Alpha Cognition stock or one of its competitors? MarketBeat compares Alpha Cognition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Cognition include Allogene Therapeutics (ALLO), Candel Therapeutics (CADL), CorMedix (CRMD), 4D Molecular Therapeutics (FDMT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Cognition compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Allogene Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Allogene Therapeutics' return on equity of -56.45% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Alpha Cognition has higher revenue and earnings than Allogene Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	31,926.38	-$190.89M	-$0.77	N/A
Alpha Cognition	$10.22M	17.15	-$20.67M	-$1.35	N/A

In the previous week, Alpha Cognition had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.19 beat Alpha Cognition's score of 0.85 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market.

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 360.66%. Alpha Cognition has a consensus price target of $16.00, suggesting a potential upside of 98.76%. Given Allogene Therapeutics' higher possible upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

83.6% of Allogene Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Alpha Cognition on 12 of the 17 factors compared between the two stocks.

How does Alpha Cognition compare to Candel Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

13.9% of Candel Therapeutics shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alpha Cognition presently has a consensus target price of $16.00, suggesting a potential upside of 98.76%. Candel Therapeutics has a consensus target price of $18.57, suggesting a potential upside of 88.16%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Cognition is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Alpha Cognition had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.03 beat Alpha Cognition's score of 0.85 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market.

Alpha Cognition has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	17.15	-$20.67M	-$1.35	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Candel Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

Alpha Cognition beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Alpha Cognition compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

CorMedix has a net margin of 45.25% compared to Alpha Cognition's net margin of -232.23%. CorMedix's return on equity of 45.57% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Alpha Cognition	-232.23%	-58.35%	-45.99%

CorMedix has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 8.6% of Alpha Cognition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CorMedix has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.13	3.88
Alpha Cognition	$10.22M	17.15	-$20.67M	-$1.35	N/A

In the previous week, Alpha Cognition had 5 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Alpha Cognition and 2 mentions for CorMedix. CorMedix's average media sentiment score of 0.86 beat Alpha Cognition's score of 0.85 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix currently has a consensus target price of $14.86, indicating a potential upside of 79.65%. Alpha Cognition has a consensus target price of $16.00, indicating a potential upside of 98.76%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

CorMedix beats Alpha Cognition on 10 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to 4D Molecular Therapeutics?

Alpha Cognition (NASDAQ:ACOG) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.7, meaning that its stock price is 170% more volatile than the broader market.

4D Molecular Therapeutics has a net margin of -182.34% compared to Alpha Cognition's net margin of -232.23%. 4D Molecular Therapeutics' return on equity of -36.83% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alpha Cognition presently has a consensus target price of $16.00, indicating a potential upside of 98.76%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 155.34%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Alpha Cognition had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 7 mentions for Alpha Cognition and 6 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.94 beat Alpha Cognition's score of 0.85 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has higher earnings, but lower revenue than 4D Molecular Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	17.15	-$20.67M	-$1.35	N/A
4D Molecular Therapeutics	$85.21M	7.18	-$140.11M	-$2.57	N/A

Summary

4D Molecular Therapeutics beats Alpha Cognition on 10 of the 16 factors compared between the two stocks.

How does Alpha Cognition compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Bright Minds Biosciences presently has a consensus price target of $143.83, indicating a potential upside of 94.29%. Alpha Cognition has a consensus price target of $16.00, indicating a potential upside of 98.76%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bright Minds Biosciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Bright Minds Biosciences' return on equity of -20.58% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Alpha Cognition	-232.23%	-58.35%	-45.99%

Bright Minds Biosciences has a beta of -5.34, suggesting that its share price is 634% less volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

In the previous week, Alpha Cognition had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Alpha Cognition and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.03 beat Alpha Cognition's score of 0.85 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bright Minds Biosciences has higher earnings, but lower revenue than Alpha Cognition. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Alpha Cognition	$10.22M	17.15	-$20.67M	-$1.35	N/A

Summary

Bright Minds Biosciences beats Alpha Cognition on 8 of the 15 factors compared between the two stocks.

Get Alpha Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACOG vs. The Competition

Export

Metric	Alpha Cognition	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$182.47M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.96	20.98	27.01	24.38
Price / Sales	17.15	311.11	522.34	92.57
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.80	8.54	10.80	6.33
Net Income	-$20.67M	$23.83M	$3.59B	$331.02M
7 Day Performance	-5.29%	-2.77%	-1.49%	-0.33%
1 Month Performance	34.39%	5.85%	2.79%	-1.29%
1 Year Performance	-22.60%	52.15%	28.56%	21.30%

Alpha Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACOG Alpha Cognition	4.517 of 5 stars	$8.05 -3.9%	$16.00 +98.8%	-23.6%	$182.47M	$10.22M	N/A	N/A	High Trading Volume
ALLO Allogene Therapeutics	2.3766 of 5 stars	$2.12 -1.4%	$8.52 +302.0%	+43.4%	$731.72M	$20K	N/A	310
CADL Candel Therapeutics	3.3054 of 5 stars	$9.88 +0.3%	$18.00 +82.2%	+53.5%	$723.91M	N/A	N/A	60	Analyst Forecast
CRMD CorMedix	3.0432 of 5 stars	$8.83 -0.5%	$14.86 +68.3%	-27.2%	$692.71M	$311.71M	4.15	30
FDMT 4D Molecular Therapeutics	1.9204 of 5 stars	$13.02 +1.6%	$29.88 +129.5%	+167.1%	$680.69M	$85.21M	N/A	120	News Coverage Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACOG) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Cognition (ACOG) Competitors

ACOG vs. ALLO, CADL, CRMD, FDMT, and DRUG

How does Alpha Cognition compare to Allogene Therapeutics?

Summary

How does Alpha Cognition compare to Candel Therapeutics?

Summary

How does Alpha Cognition compare to CorMedix?

Summary

How does Alpha Cognition compare to 4D Molecular Therapeutics?

Summary

How does Alpha Cognition compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Cognition (ACOG) Competitors

ACOG vs. ALLO, CADL, CRMD, FDMT, and DRUG

How does Alpha Cognition compare to Allogene Therapeutics?

Is ALLO or ACOG more profitable?

Which has better earnings & valuation, ALLO or ACOG?

Does the media prefer ALLO or ACOG?

Which has more volatility and risk, ALLO or ACOG?

Do analysts recommend ALLO or ACOG?

Do institutionals and insiders hold more shares of ALLO or ACOG?

Summary

How does Alpha Cognition compare to Candel Therapeutics?

Do institutionals & insiders hold more shares of ACOG or CADL?

Do analysts recommend ACOG or CADL?

Does the media favor ACOG or CADL?

Which has more volatility & risk, ACOG or CADL?

Which has stronger valuation & earnings, ACOG or CADL?

Is ACOG or CADL more profitable?

Summary

How does Alpha Cognition compare to CorMedix?

Is CRMD or ACOG more profitable?

Which has more risk & volatility, CRMD or ACOG?

Do insiders & institutionals have more ownership in CRMD or ACOG?

Which has better valuation & earnings, CRMD or ACOG?

Does the media prefer CRMD or ACOG?

Do analysts rate CRMD or ACOG?

Summary

How does Alpha Cognition compare to 4D Molecular Therapeutics?

Which has more risk & volatility, ACOG or FDMT?

Is ACOG or FDMT more profitable?

Do institutionals & insiders have more ownership in ACOG or FDMT?

Do analysts prefer ACOG or FDMT?

Does the media favor ACOG or FDMT?

Which has stronger earnings and valuation, ACOG or FDMT?

Summary

How does Alpha Cognition compare to Bright Minds Biosciences?

Do analysts prefer DRUG or ACOG?

Is DRUG or ACOG more profitable?

Which has more risk and volatility, DRUG or ACOG?

Does the media prefer DRUG or ACOG?

Do institutionals and insiders believe in DRUG or ACOG?

Which has preferable earnings and valuation, DRUG or ACOG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACOG vs. The Competition

Alpha Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools